PMID- 29623079
OWN - NLM
STAT- MEDLINE
DCOM- 20190501
LR  - 20190501
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 9
DP  - 2018
TI  - The Significance of Tumor Necrosis Factor Receptor Type II in CD8(+) Regulatory T 
      Cells and CD8(+) Effector T Cells.
PG  - 583
LID - 10.3389/fimmu.2018.00583 [doi]
LID - 583
AB  - Tumor necrosis factor (TNF) is a pleiotropic cytokine that has both 
      pro-inflammatory and anti-inflammatory functions. The biological functions of TNF 
      are mediated by two receptors, TNF receptor type I (TNFR1) and TNF receptor type 
      II (TNFR2). TNFR1 is expressed universally on almost all cell types and has been 
      extensively studied, whereas TNFR2 is mainly restricted to immune cells and some 
      tumor cells and its role is far from clarified. Studies have shown that TNFR2 
      mediates the stimulatory activity of TNF on CD4(+)Foxp3(+) regulatory T cells 
      (Tregs) and CD8(+)Foxp3(+) Tregs, and is involved in the phenotypic stability, 
      proliferation, activation, and suppressive activity of Tregs. TNFR2 can also be 
      expressed on CD8(+) effector T cells (Teffs), which delivers an activation signal 
      and cytotoxic ability to CD8(+) Teffs during the early immune response, as well 
      as an apoptosis signal to terminate the immune response. TNFR2-induced abolition 
      of TNF receptor-associated factor 2 (TRAF2) degradation may play an important 
      role in these processes. Consequently, due to the distribution of TNFR2 and its 
      pleiotropic effects, TNFR2 appears to be critical to keeping the balance between 
      Tregs and Teffs, and may be an efficient therapeutic target for tumor and 
      autoimmune diseases. In this review, we summarize the biological functions of 
      TNFR2 expressed on CD8(+)Foxp3(+) Tregs and CD8(+) Teffs, and highlight how TNF 
      uses TNFR2 to coordinate the complex events that ultimately lead to efficient 
      CD8(+) T cell-mediated immune responses.
FAU - Ye, Lin-Lin
AU  - Ye LL
AD  - Department of Respiratory Medicine, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Wei, Xiao-Shan
AU  - Wei XS
AD  - Department of Respiratory Medicine, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Zhang, Min
AU  - Zhang M
AD  - Department of Respiratory Medicine, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Niu, Yi-Ran
AU  - Niu YR
AD  - Department of Respiratory Medicine, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Zhou, Qiong
AU  - Zhou Q
AD  - Department of Respiratory Medicine, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180322
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
SB  - IM
MH  - Animals
MH  - Apoptosis/immunology
MH  - Biomarkers
MH  - CD8-Positive T-Lymphocytes/immunology/*metabolism
MH  - Cytotoxicity, Immunologic
MH  - Gene Expression Regulation
MH  - Humans
MH  - Immunity
MH  - Immunologic Memory
MH  - Lymphocyte Activation/immunology
MH  - Phenotype
MH  - Protein Binding
MH  - Receptors, Tumor Necrosis Factor, Type II/genetics/*metabolism
MH  - Signal Transduction
MH  - T-Lymphocyte Subsets/immunology/*metabolism
MH  - T-Lymphocytes, Regulatory/immunology/*metabolism
PMC - PMC5874323
OTO - NOTNLM
OT  - CD4+ regulatory T cells
OT  - CD8+ effector T cells
OT  - CD8+ regulatory T cells
OT  - tumor necrosis factor
OT  - tumor necrosis factor receptor type II
EDAT- 2018/04/07 06:00
MHDA- 2018/04/07 06:01
PMCR- 2018/01/01
CRDT- 2018/04/07 06:00
PHST- 2017/12/31 00:00 [received]
PHST- 2018/03/08 00:00 [accepted]
PHST- 2018/04/07 06:00 [entrez]
PHST- 2018/04/07 06:00 [pubmed]
PHST- 2018/04/07 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2018.00583 [doi]
PST - epublish
SO  - Front Immunol. 2018 Mar 22;9:583. doi: 10.3389/fimmu.2018.00583. eCollection 
      2018.